This demonstrates not only that SPT5 is an attractive candidate for targeting MYC-mediated oncogenic growth, but also suggests that inhibition of an essential process, such as transcription, could open a therapeutic window in tumor treatment. Here, SUPT5H is linked to neoplasm.